ReviewInfectious diseases and therapy2026
The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ceftriaxone for methicillin-susceptibleAnnals of medicine · 2026Pooled it
- ADVANCE-ID bacterial and fungal infections review: antimicrobial resistance research updates.JAC-antimicrobial resistance · 2026Article
- Cefazolin Versus Antistaphylococcal Penicillins in Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Review
- Development of a rapid diagnostic test for the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus: Cefinase disk direct (CDD) test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-susceptible Staphylococcus aureus (MSSA) remains a major cause of morbidity and mortality worldwide, particularly owing to its role in complicated infections including bloodstream infections, osteomyelitis, and infective endocarditis. In 2017, an estimated 119,247 cases of S. aureus bloodstream infections were reported in the USA, resulting in approximately 19,832 deaths. While the prevalence of MSSA varies by region and demographic factors, MSSA has been reported to be approximately two times more common than methicillin-resistant S. aureus (MRSA) in both total and complicated infections. Cefazolin, a first-generation cephalosporin, is widely used for MSSA treatment owing to its favorable safety profile, cost-effectiveness, and availability. However, its efficacy may be compromised by the cefazolin inoculum effect (CzIE)-a phenomenon where cefazolin activity diminishes at high bacterial densities, such as those found in endocardial vegetations or abscesses. Importantly, CzIE is not universally present across all MSSA isolates and geographical areas, with reported prevalence ranging from 0% to 55%. Initially considered a result of producing specific allotypes of the staphylococcal β-lactamase enzyme BlaZ (i.e., allotypes A and C), recent work sheds new light on different BlaZ allotypes associated with the effect while establishing that no single genetic determinant or allotype is uniquely and definitively responsible. When present, CzIE can lead to elevated cefazolin MICs at high inocula, potentially resulting in treatment failure, prolonged hospitalization, and increased mortality. Despite these concerns, clinical data remain inconclusive, and the true impact of CzIE on patient outcomes is still under investigation. This review critically evaluates the molecular basis, clinical relevance, and diagnostic challenges of CzIE, with the goal of informing antibiotic stewardship and optimizing treatment strategies for serious MSSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.